BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System
Boston Scientific Corporation today announced it has received CE Mark approval for its TAXUS Element Paclitaxel-Eluting Coronary Stent System, the Company’s third-generation drug-eluting stent technology. This approval includes a specific indication for the treatment of diabetic patients.

Read more on News-Medical-Net

More Meth Drug Addiction Info:

• Boston Scientific Announces European Approval Of Platinum Chromium …
• Uncontrolled diabetes and hypertension high in New Delhi, says …
• Natco's Albupax (paclitaxel) breast cancer drug has high toxin …
• Biz reporters barred from Boston Scientific annual meeting …
• Diabetes mellitus Risks, Symptoms, Causes, Diagnosis and Treatment …
• Diabetes mellitus Risks, Symptoms, Causes, Diagnosis and Treatment …
• Diabetes mellitus Risks, Symptoms, Causes, Diagnosis and Treatment …
• White Sun on Health – Diabetes | Payad.com [FREE CLASSIFIED ADs]
• Atrium Medical Corporation Announces First Implant Of CINATRA …
• Complications of diabetes mellitus